Overproduction of thrombopoietin byBRAFV600E‐mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis-Reference-Cited by-同舟云学术

Overproduction of thrombopoietin byBRAFV600E‐mutated mouse hepatocytes and contribution of thrombopoietin to hepatocarcinogenesis

Published:2019-07-30 Issue:9 Volume:110 Page:2748-2759
ISSN:1347-9032
Container-title:Cancer Science
language:en
Short-container-title:Cancer Sci

Author:

Tanaka Hiroki¹,Horioka Kie¹,Yamamoto Masahiro²,Asari Masaru¹,Okuda Katsuhiro¹,Yamazaki Kosuke³,Shimizu Keiko¹,Ogawa Katsuhiro⁴^ORCID

Affiliation:

1. Department of Legal Medicine Asahikawa Medical University Asahikawa Japan

2. Department of Molecular Cancer Science School of Medicine Yamagata University Yamagata Japan

3. Department of Clinical Medicine Surgery Area Japanese Red Cross Hokkaido College of Nursing Kitamai Japan

4. Department of Pathology Asahikawa Medical University Asahikawa Japan

Funder

Ministry of Education, Culture, Sports, Science and Technology

Publisher

Wiley

Subject

Cancer Research,Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cas.14130

Reference40 articles.

1. Liver Cancer Cell of Origin, Molecular Class, and Effects on Patient Prognosis

2. Experimental mouse models for hepatocellular carcinoma research

3. Preneoplastic and neoplastic progression during hepatocarcinogenesis in mice injected with diethylnitrosamine in infancy.

4. Mutational activation of the c-Ha-ras gene in liver tumors of different rodent strains: correlation with susceptibility to hepatocarcinogenesis.

5. Incidence of mutation at codon 61 of the Ha‐ras gene in liver tumors of mice genetically susceptible and resistant to hepatocarcinogenesis;Dragani TA;Oncogene,1991

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Exploring the Role of Platelets in Virus-Induced Inflammatory Demyelinating Disease and Myocarditis;International Journal of Molecular Sciences;2024-03-19

2. Treatment of hepatocellular carcinoma with autologous platelets encapsulating sorafenib or lenvatinib: A novel therapy exploiting tumor‐platelet interactions;International Journal of Cancer;2021-12-29